XORTX Therapeutics Inc
XRTX0.560USD
-0.016-2.74%
收盘 12/24, 13:00（美东）报价延迟15分钟
2.92M总市值
亏损市盈率 TTM
关于 XORTX Therapeutics Inc 公司
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
XORTX Therapeutics Inc简介
公司代码XRTX
公司名称XORTX Therapeutics Inc
上市日期Sep 30, 2015
CEODavidoff (Allen W)
员工数量2
证券类型Ordinary Share
年结日Sep 30
公司地址3710 - 33rd Street NW
城市CALGARY
上市交易所NASDAQ OMX - NASDAQ BASIC
国家Canada
邮编T2L 2M1
电话14034557727
网址https://www.xortx.com/
公司代码XRTX
上市日期Sep 30, 2015
CEODavidoff (Allen W)
XORTX Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
--
--
Ms. Abigail Jenkins
Ms. Abigail Jenkins
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Mr. William (Bill) Farley
Mr. William (Bill) Farley
Independent Director
Independent Director
--
--
Mr. Patrick Treanor
Mr. Patrick Treanor
Independent Director
Independent Director
--
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月17日 周一
更新时间: 11月17日 周一
持股股东
股东类型
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
其他
88.47%
持股股东
持股股东
占比
Lincoln Alternative Strategies LLC
8.22%
Davidoff, Allen Warren
1.73%
Citadel Advisors LLC
1.24%
XTX Markets LLC
0.20%
Giovinazzo (Anthony)
0.14%
其他
88.47%
股东类型
持股股东
占比
Corporation
8.22%
Individual Investor
1.87%
Hedge Fund
1.24%
Venture Capital
0.20%
其他
88.47%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
16
63.97K
1.23%
-645.66K
2025Q2
17
129.44K
3.30%
-739.58K
2025Q1
20
127.29K
3.49%
-606.22K
2024Q4
21
385.20K
10.34%
-244.07K
2024Q3
22
287.39K
12.35%
-145.77K
2024Q2
20
276.67K
12.12%
-141.93K
2024Q1
21
272.84K
13.24%
-121.02K
2023Q4
19
553.49K
27.69%
+481.09K
2023Q3
20
176.53K
8.83%
-185.14K
2023Q2
19
179.60K
8.98%
-178.94K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Davidoff, Allen Warren
120.45K
2.31%
+8.19K
+7.30%
Jul 22, 2025
Citadel Advisors LLC
38.47K
0.74%
+38.47K
--
Jun 30, 2025
Giovinazzo (Anthony)
9.63K
0.18%
--
--
Apr 30, 2025
RBC Dominion Securities, Inc.
--
0%
-1.49K
-100.00%
Mar 31, 2025
Van Damme (Paul Joseph)
7.11K
0.14%
--
--
Apr 30, 2025
Clearstead Advisors LLC
277.00
0.01%
--
--
Jun 30, 2025
UBS Financial Services, Inc.
20.79K
0.4%
+20.79K
--
Jun 30, 2025
查看更多
持股ETF
机构名称
占比
暂无数据
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
公告日期
类型
比率
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
Oct 12, 2023
Merger
9→1
常见问题
XORTX Therapeutics Inc的前五大股东是谁？
XORTX Therapeutics Inc 的前五大股东如下：
Davidoff, Allen Warren持有股份：120.45K，占总股份比例：2.31%。
Citadel Advisors LLC持有股份：38.47K，占总股份比例：0.74%。
Giovinazzo (Anthony)持有股份：9.63K，占总股份比例：0.18%。
RBC Dominion Securities, Inc.持有股份：0.00，占总股份比例：0.00%。
Van Damme (Paul Joseph)持有股份：7.11K，占总股份比例：0.14%。
Davidoff, Allen Warren持有股份：120.45K，占总股份比例：2.31%。
Citadel Advisors LLC持有股份：38.47K，占总股份比例：0.74%。
Giovinazzo (Anthony)持有股份：9.63K，占总股份比例：0.18%。
RBC Dominion Securities, Inc.持有股份：0.00，占总股份比例：0.00%。
Van Damme (Paul Joseph)持有股份：7.11K，占总股份比例：0.14%。
XORTX Therapeutics Inc的前三大股东类型是什么？
XORTX Therapeutics Inc 的前三大股东类型分别是：
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
Lincoln Alternative Strategies LLC
Davidoff, Allen Warren
Citadel Advisors LLC
有多少机构持有XORTX Therapeutics Inc(XRTX)的股份？
截至2025Q3，共有16家机构持有XORTX Therapeutics Inc的股份，合计持有的股份价值约为63.97K，占公司总股份的1.23%。与2025Q2相比，机构持股有所增加，增幅为-2.08%。
哪个业务部门对XORTX Therapeutics Inc的收入贡献最大？
在--，--业务部门对XORTX Therapeutics Inc的收入贡献最大，创收--，占总收入的--%。
